**** Elite Pharmaceuticals Conference Call Questions ****
Shareholders participating in the Conference Call are typically allowed to ask 1 or 2 questions following the company's prepared statements.
To make the most of this Q&A opportunity with ELTP management, suggest that we come up with a list to share of top questions to ask:
(Copy/paste and add your question(s) at the end of the latest posted list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
2. Please explain the purpose for the upcoming meeting in October with the FDA. Best case and worst case scenario.
3. With so much going on will Analyst be reassess-updating last Falls value of Elite for future negotiations?
6. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
7. 2 FDA applications ... what info can we get? How long have they been in the system?
8. 11 ANDA's for site transfer, what's going on?
9. Any plans for Eli-154?
10. What's the next step for Eli-201?
11. What's going on with the three drugs in Scale up?
12. Any generics moving up the ladder to commercialization?
13. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated
as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
13. In July, the FDA approved Purdue's Targiniq ER with labeling describing the product's abuse-deterrent properties. Is ELTP's ART more effective than Purdue's? If so, is it likely that the FDA will also approve ELTP's ART products?
14. ELTP has been severely criticized by some people for not revealing the name of the independent analyst who valued ELTP from .40(worst case) to 2.75 (best case). Can you please tell us the analyst's name (or at least tell us why you won't tell us)?
